GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ThermoGenesis Holdings Inc (NAS:THMO) » Definitions » ROE %

ThermoGenesis Holdings (ThermoGenesis Holdings) ROE % : -1,916.39% (As of Dec. 2023)


View and export this data going back to 1987. Start your Free Trial

What is ThermoGenesis Holdings ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. ThermoGenesis Holdings's annualized net income for the quarter that ended in Dec. 2023 was $-28.06 Mil. ThermoGenesis Holdings's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $1.46 Mil. Therefore, ThermoGenesis Holdings's annualized ROE % for the quarter that ended in Dec. 2023 was -1,916.39%.

The historical rank and industry rank for ThermoGenesis Holdings's ROE % or its related term are showing as below:

THMO' s ROE % Range Over the Past 10 Years
Min: -1367.44   Med: -208.7   Max: -27.83
Current: -524.39

During the past 13 years, ThermoGenesis Holdings's highest ROE % was -27.83%. The lowest was -1,367.44%. And the median was -208.70%.

THMO's ROE % is ranked worse than
98.39% of 805 companies
in the Medical Devices & Instruments industry
Industry Median: 0.25 vs THMO: -524.39

ThermoGenesis Holdings ROE % Historical Data

The historical data trend for ThermoGenesis Holdings's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ThermoGenesis Holdings ROE % Chart

ThermoGenesis Holdings Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -215.16 -528.65 -236.37 -277.45 -1,367.44

ThermoGenesis Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -292.33 -392.10 -182.35 -343.10 -1,916.39

Competitive Comparison of ThermoGenesis Holdings's ROE %

For the Medical Devices subindustry, ThermoGenesis Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ThermoGenesis Holdings's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ThermoGenesis Holdings's ROE % distribution charts can be found below:

* The bar in red indicates where ThermoGenesis Holdings's ROE % falls into.



ThermoGenesis Holdings ROE % Calculation

ThermoGenesis Holdings's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-17.975/( (4.296+-1.667)/ 2 )
=-17.975/1.3145
=-1,367.44 %

ThermoGenesis Holdings's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-28.056/( (4.595+-1.667)/ 2 )
=-28.056/1.464
=-1,916.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


ThermoGenesis Holdings  (NAS:THMO) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-28.056/1.464
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-28.056 / 9.624)*(9.624 / 13.5765)*(13.5765 / 1.464)
=Net Margin %*Asset Turnover*Equity Multiplier
=-291.52 %*0.7089*9.2736
=ROA %*Equity Multiplier
=-206.66 %*9.2736
=-1,916.39 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-28.056/1.464
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-28.056 / -30.396) * (-30.396 / -8.968) * (-8.968 / 9.624) * (9.624 / 13.5765) * (13.5765 / 1.464)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.923 * 3.3894 * -93.18 % * 0.7089 * 9.2736
=-1,916.39 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


ThermoGenesis Holdings ROE % Related Terms

Thank you for viewing the detailed overview of ThermoGenesis Holdings's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


ThermoGenesis Holdings (ThermoGenesis Holdings) Business Description

Traded in Other Exchanges
Address
2711 Citrus Road, Rancho Cordova, CA, USA, 95742
ThermoGenesis Holdings Inc develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. It offers the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for bio-manufacturing for immuno-oncology applications.
Executives
Xiaochun Xu director 2453 S. ARCHER AVE., STE. B, CHICAGO IL 60616
Biao Xi director C/O THERMOGENESIS HOLDINGS, INC., 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
James Xu director 2453 S. ARCHER AVE, SUITE B, CHICAGO IL 60616
Haihong Zhu director 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Debra Donaghy director C/O THERMOGENESIS HOLDINGS, INC., 2711 CITRUS RD., RANCHO CORDOVA CA 95742
Boyalife (hong Kong) Ltd 10 percent owner 2453 S. ARCHER AVE., STE. B, CHICAGO IL 60616
Thomis Joseph director MALEIZENSTRAAT 66, HERENT C9 B-3020
Boyalife Asset Holding Ii, Inc. 10 percent owner 2453 S. ARCHER AVE., SUITE B, CHICAGO IL 60616
Boyalife Group, Inc. 10 percent owner 2453 S. ARCHER AVE., SUITE B, CHICAGO IL 60616
Russell M Medford director 7935 FAWNDALE WAY, ATLANTA GA 30350
Mark Westgate director 350 CORPORATE BOULEVARD, ROBBINSVILLE NJ 08691
Jeffery Cauble officer: Principal Accounting Officer 2711 CITRUS CT., RANCHO CORDOVA CA 95742
Vivian H Liu director
Boyalife Investment Inc. 10 percent owner 2453 S. ARCHER AVE., STE. B, CHICAGO IL 60616
Mark Bagnall director 3876 BAY CENTER PLACE, HAYWARD CA 94545

ThermoGenesis Holdings (ThermoGenesis Holdings) Headlines

From GuruFocus

THERMOGENESIS CLOSES $2.05 MILLION PUBLIC OFFERING

By PRNewswire PRNewswire 10-28-2022